Systemic Treatments for the Management of Prurigo Nodularis
A dermatology expert provides comprehensive insights into prurigo nodularis, discussing its disproportionate impact on middle-aged adults and immunocompromised individuals, the evolution of treatment from traditional dermatologic therapies to FDA-approved biologics (dupilumab and nemolizumab), and the importance of addressing both the physical symptoms and psychological burden while considering patient-specific factors such as comorbidities in treatment selection.
EP. 1: Understanding Patient Comorbidities and Burden of Disease in Prurigo Nodularis
December 20th 2024A panelist discusses how prurigo nodularis is a chronic inflammatory skin condition that disproportionately affects middle-aged adults and those with immune disorders, causing intensely pruritic nodules that significantly impact quality of life through both physical discomfort and psychological distress.
EP. 2: Advances in Systemic Treatment Options for Prurigo Nodularis
December 20th 2024A panelist discusses how the treatment landscape for prurigo nodularis (PN) has evolved from primarily using topical therapies and off-label systemic medications to incorporating FDA-approved targeted biologics such as dupilumab and nemolizumab, which have demonstrated significant efficacy in reducing both the itchiness and nodular lesions.
EP. 3: Managing Moderate Prurigo Nodularis in a 52-Year-Old Female With Atopic Dermatitis
January 2nd 2025A panelist discusses how diagnostic differentiation of prurigo nodularis requires careful examination of the characteristic firm, hyperkeratotic nodules and consideration of the patient's history of chronic pruritus and scratching behavior, while noting that comorbid atopic dermatitis may influence treatment selection toward dual-targeting therapies.
EP. 5: Practice Pearls for Managing Patients With Prurigo Nodularis
January 17th 2025A panelist discusses how the advent of targeted systemic therapies such as dupilumab and nemolizumab has transformed the treatment landscape for prurigo nodularis, offering more effective options for breaking the itch-scratch cycle while maintaining favorable safety profiles compared with traditional systemic treatments.
